Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile

Vertex Pharmaceuticals Hits Record High on Strong Q1 EarningsEntrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory patients with Duc